StocksNovo Nordisk B A/SNOVO-B.CO

NOVO-B.CO

Novo Nordisk B A/S

762.16 -3.44 (-0.45%)
Prices By Xignite, in DKK Market Closed
Trade
S
762.16
B
764.75

Overview

Prev Close765.60
Day's Range 756.76 - 767.85
52 Week Range 603.86 - 862.72
Average Volume (3m)1.67M
1-Year Return22.80%
Beta1.086
Market Cap1.72T
P/E Ratio34.5
Revenue157.25B
EPS22.1679
Dividend (Yield)8.15 (1.07%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.722/04/202207/07/202213/09/2022750.00775.00800.00825.00850.00875.00
Chart times in UTC
Industry Pharmaceuticals Major
CEO Lars Fruergaard Jørgensen, MBA
Employees 47,792

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Novo Nordisk B A/S's revenues increased by 10.91% and amounted to 140.80B. Net income increased by 13.33% to 47.76B. Net assets increased by 11.72% to 70.75B and EPS increased from 18.01 to 20.74.
NOVO-B.CO's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
83.92%
Net Profit Margin
33.54%
Operating Margin
41.85%
Return On Investment
67.20%
09/21
12/21
03/22
06/22
Total Revenue
35.62B
38.33B
42.03B
41.27B
Gross Profit
29.56B
32.09B
35.11B
35.2B
Operating Income
15.17B
13.64B
18.76B
18.24B
Net Income
12.12B
10.89B
14.21B
13.32B